TABLE 2.
Antimicrobial and regimen | Total daily dose (g) | MIC50/MIC90 (μg/ml) |
PTA (%) |
||||
---|---|---|---|---|---|---|---|
Monotherapy |
Combination therapy |
||||||
Monotherapy | Combination therapy | MIC50 | MIC90 | MIC50 | MIC90 | ||
Fosfomycin | 128/512 | 16/64 | |||||
4 g i.v. q8h | 12 | 0 | 0 | 89 | 16 | ||
4 g i.v. q6h | 16 | 0.4 | 0 | 94 | 33 | ||
6 g i.v. q8h | 18 | 3.1 | 0 | 96 | 46 | ||
8 g i.v. q8h | 24 | 16 | 0 | 98 | 64 | ||
Meropenem (0.5-h infusion) | 16/512 | 2/64 | |||||
1 g q8h | 3 | 61 | 0 | 98 | 2.5 | ||
1.5 g q6h | 6 | 87 | 0 | 99 | 14 | ||
2 g q8h | 6 | 85 | 0 | 99 | 21 | ||
Meropenem (3-h infusion) | |||||||
1 g q8h | 3 | 67 | 0 | 99 | 4.1 | ||
1.5 g q6h | 6 | 91 | 0 | 100 | 13 | ||
2 g q8h | 6 | 88 | 0 | 100 | 22 |
The pharmacodynamic surrogate index for fosfomycin was an fAUC/MIC of 40.8 for a CLCR of >40 ml/min, and that for meropenem was an ƒT>MIC of 40% for a CLCR of >50 ml/min.